NPPA Seeks Market Data From Orthopaedic Knee Implant Manufacturers And Importers

New Delhi : The importers and manufacturers of knee implants may need to furnish data relating to their supplies, the prices among others with the pricing authority, in order for the government to keep a tab on the prices of medical devices.

The National Pharmaceutical Pricing Authority (NPPA) has directed the importers and manufacturers of knee implants for knee replacement systems to furnish data relating to orthopaedic knee implants. It has also prescribed a format in which the details to be submitted.

The details have to be submitted on almost 18 categories of products made of different materials. They should specify whether it is imported or domestically manufactured, the price to distributor or the price to stockist on June 30, 2021, maximum retail price on June 30, 2021, quantity sold and moving annual turnover for the period from July 2020 and June 2021 and from July 2019 to June 2020.

The information should be submitted with the NPPA by August 12, 2021, it directed the companies dealing with orthopaedic knee implant system.

It may be noted that the NPPA has recently imposed a cap on the trade margin of pulse oximeter, blood pressure monitoring machine, nebuliser, digital thermometer and gloucometer, at 70 per cent at the price to distributor (PTD) level.

It was further notified that the prices are to be revised by the manufacturers or importers as per the formula prescribed in the notification and the revised prices shall be effective from July 20, 2021. As per the direction from the Authority, over a thousand brands submitted their old price and revised price in a prescribed format in a few weeks, and a majority of the brands reduced the prices according to this, said NPPA officials earlier.

[pdf-embedder url=”https://medicarepharmabusiness.com/wp-content/uploads/2021/08/OM_dated-04.08.2021_Orthopaedic-Knee-Implants-050821081128.pdf”]

  • Related Posts

    • Pharma
    • July 22, 2025
    • 70 views
    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

    • Pharma
    • July 16, 2025
    • 479 views
    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

    Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

    Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

    Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end